Prostate Cancer - A Therapeutic and Competitive Insight

Cancer of the prostate is the second most frequently diagnosed cancer in men in the US. Several new approvals have changed the panorama for options in the treatment of late stage prostate cancer. Abarelix was approved in November 2003 for the palliative treatment of men with advanced symptomatic prostate cancer. In May 2004 docetaxel was approved for use in combination with prednisone as a treatment for patients with androgen independent (hormone refractory) metastatic prostate cancer. Additionally, in October 2004 FDA approved histrelin for the palliative treatment of advanced prostate cancer. Finally, leuprolide was approved by FDA in January 2002 for the palliative treatment of advanced prostate cancer. One example of market penetration in this field is that analysts forecasts Abarelix a sales of $450 million in 2006.

Research and analysis highlights

In the report "Prostate Cancer - A Therapeutic & Competitive Insight" BioSeeker does not only describe and analyze the latest years of progress but as well provide an insight and framework to understand the complex field of prostate cancer therapeutics. In this report, we provide one of the most comprehensive coverage of the R&D trends to set the future marketplace. BioSeeker presents both an overview and a detailed description on the progress of key drugs in Phase III and II development, together with general descriptions on drugs and targets. We have identified 127 drug candidates in phase II or III stage of development and more than 85 companies are involved in the development of these drugs. Among these drugs we clearly see substantial progress while others have failed. There will be a more intense competition in this market and current treatments will be changed for the benefit of more innovative therapies.

Scope of this report

Thorough examination of status and impact of several novel drugs in development

Discussion of the challenges in current and future treatment strategies

Anticancer pipeline of most companies in the field

Key reasons to read this report

Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in prostate cancer R&D, and the results of clinical trials to date

Gain insight into the current challenges and commercial opportunities associated with prostate cancer therapy

One hundred high quality references

Some of the drugs included in this analysis:

toremifene, bevacizumab, oblimersen sodium, R-flurbiprofen, sipuleucel-T, satraplatin, GVAX, exisulind, vapreotide, DCVax-prostate, epothilone D, ixabepilone, PTK/ZK, arsenic trioxide,retinoic acid, imatinib, bortezomib, sorafenib tosylate, doxorubicin etc.

Some of the companies included in this analysis:

Orion Pharma, Genentech, Genta, Encore Pharmaceuticals, Dendreon, Johnson Matthey, Cell Genesys, OSI Pharmaceuticals, Debiopharm, Northwest Biotherapeutics, Kosan Biosciences, Bristol-Myers Squibb, Cephalon, Antigenics, Novartis, Millennium, Bayer, Johnson & Johnson etc

Pages: 99 January 2007
Table of Contents
Price: $2,999.00 / GBP1,499.50